The impact of lipid-lowering treatment patterns on LDL-C reduction and goal attainment in secondary prevention in Germany

Prevention and Control

Volumn 2, Issue 1, 2006, Pages 15-26

  Rajagopalan, Srinivasan ^a   Vieira, José Luiz ^b   Alemao, Evo ^c   Yin, Donald ^c   Moriguchi, Emilio H ^b  

^a Med Data Analytics Inc   (United States)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Goal attainment; Lipid lowering therapy; Prescription persistence; Treatment patterns

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESIN; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DRUG DOSE REGIMEN; DRUG POTENCY; DRUG SUBSTITUTION; FEMALE; GERMANY; HUMAN; HYPERLIPIDEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MONOTHERAPY; MORBIDITY; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOM SAMPLE; RETROSPECTIVE STUDY; SECONDARY PREVENTION; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 33746971449     PISSN: 15732088     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.precon.2006.06.010     Document Type: Article

References (32)

1. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 248 (1982) 1465-1477
2. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 334 (1994) 1383-1389
3. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 333 (1995) 1301-1307
4. Cholesterol and Recurrent Events (CARE) Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 335 (1996) 1001-1009
5. The LIPID Study Group. Prevention of cardiovascular events with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 339 (1998) 1349-1357
6. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622
7. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive Summary. National Cholesterol Education Program. National Heart, Lung, and Blood Institute, National Institutes of Health. NIH Publication No. 01-3670; May 2001.
8. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., and Pyoraia K. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Atherosclerosis 140 (1998) 199-270
9. McBride P., Schrott H., Plane M., Underbakke G., and Brown R.L. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 158 (1998) 1238-1244
10. Stafford R., Blumenthal D., and Pasternak R. Variations in cholesterol management practices of US physicians. J Am Coll Cardiol 29 (1997) 139-146
11. Frolklis J.P., Zyzanski S.J., Schwartz J.M., and Sushan P.S. Physician noncompliance with the National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation 98 (1998) 851-855
12. Cohen M., Byrne M., Levine B., Gutowski T., and Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation 83 (1991) 1294-1304
13. EUROASPIRE Study Group. A European Society of Cardiology survey on secondary prevention of coronary heart disease: principal results. Eur Heart J 18 (1997) 1569-1582
14. Shepherd J., Alcalde V., and Befort P.-A. International comparison of awareness and attitudes towards coronary risk factor reduction: the HELP study. J Cardiovasc Risk 4 (1997) 373-384
15. Unwin N., Thomson R., O'Byrne A.M., Laker M., and Armstrong H. Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors. Br Medical J 317 (1998) 1125-1130
16. Campbell N.C., Thain J., Deans G., Ritchie L.D., and Rawles J.M. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. Br Medical J 316 (1998) 1430-1434
17. Andrade S.E., Walker A.M., Gottlieb L.K., et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings?. New Engl J Med 332 (1995) 1125-1131
18. Majumdar S.R., Gurwitz J.H., and Soumerai S.B. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 14 (1999) 711-717
19. Willich S.N., Muller-Nordhorn J., Kulig M., et al. Cardiac risk factors, medication, and recurrent clinical events after acute coronary disease; a prospective cohort study. Eur Heart J 22 (2001) 307-313
20. Yang C., Jick S.S., and Testa M.A. Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of co-morbidities and patient characteristics. Br J Clin Pharmacol 56 (2003) 84-91
21. Krobot K.J., Yin D.D., Alemao E., and Steinhagen-Thiessen E. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with CHD: relation to pretreatment LDL cholesterol, pretreatment CHD risk, and other factors. Eur J Cardiovasc Prevention Rehab 12 (2005) 37-45
22. Maron D.J., Fazio S., and Linton M.F. Current perspectives on statins. Circulation 101 (2000) 207-213
23. Benner J.S., Glynn R.J., Mogun H., Neumann P.J., Weinstein M.C., and Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 288 (2002) 455-461
24. Eaton C.B., Galliher J.M., McBride P.E., et al. Family physician's knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey. J Am Board Fam Med 19 (2006) 46-53
25. Heidrich J., Behrens T., and Keil U. Knowledge and perception of guidelines and secondary prevention of coronary heart disease among general practitioners and internists. Results from a physician survey in Germany. Eur J Cardiovasc Prev Rehabil 12 (2005) 521-529
26. McDermott M.M., Hahn E.A., Cella D., et al. Atherosclerotic risk factor reduction in peripheral arterial disease: results of a national physician survey. J Gen Intern Med 17 (2002) 895-904
27. Cannon C.P., Braunwald E., McCabe C.H., et al. Comparison of intensive and moderate lipid-lowering with statins after acute coronary syndromes. New Engl J Med 350 (2004) 1495-1504
28. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
29. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo controlled trial. Lancet 360 (2002) 7-22
30. Ito M.K., Delucca G.M., and Aldridge M.A. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-related events. J Cardiovasc Pharmacol Ther 6 (2001) 129-135
31. Carlsson Å., Borgström F., Stålhammar J., Alemao E., Yin D., and Jönsson L. Costs of care for patients treated with lipid-lowering drugs. PharmacoEonomics 22 Suppl. 3 (2004) 25-35
32. Roberts W.C. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 80 1 (1997) 106-107